Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors.

Abstract

The radiosensitizing efficacy of SR-2508, a new 2-nitroimidazole, which is less neurotoxic than misonidazole (MISO) was studied using transplantable mammary carcinoma of C3H/He mice. Tumor responses to treatments were evaluated by growth-delay time assay. In single irradiations, the enhancement ratios of 0.5 mmole/kg of MISO and 1.5 mmole/kg of SR-2508, which were equitoxic to C3H/He mice, were 1.42 and 1.84 respectively. In fractionated irradiations with three fractions over two days or five fractions over four days, the enhancement ratios of 1.5 mmole/kg of SR-2508 were 1.40 and 1.34 respectively. On the other hand the enhancement ratios of MISO at the above mentioned dose in respective fractionated irradiations were 1.15 or 1.11. SR-2508 is considered promising as a hypoxic cell radiosensitizer for clinical use.

• Authors: K Ono, M Takahashi, T Nishidai, Y Dodo, Y Shibamoto, M Hiraoka, Y Yukawa, M Abe
• Journal: Radiation medicine (Radiat Med) 1984 Jan-Mar Vol. 2 Issue 1 Pg. 71-5 ISSN: 0288-2043 [Print] Japan
• PMID: 6242712 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Nitroimidazoles
• Radiation-Sensitizing Agents
• Etanidazole
• Misonidazole

Topics

• Animals
• Etanidazole
• Female
• Mammary Neoplasms, Experimental (radiotherapy)
• Mice
• Mice, Inbred C3H
• Misonidazole (therapeutic use)
• Neoplasm Transplantation
• Nitroimidazoles (therapeutic use)
• Radiation-Sensitizing Agents
• Radiotherapy Dosage
• Radiotherapy, High-Energy